Please login to the form below
China biotech
This page shows the latest China biotech news and features for those working in and with pharma, biotech and healthcare.
Biogen pays InnoCare $125m upfront for potential multiple sclerosis treatment
As part of the agreement, Biogen will gain exclusive rights to the orelabrutinib for MS and certain undisclosed autoimmune diseases globally outside China (including Hong Kong, Macau and Taiwan). ... InnoCare will retain exclusive worldwide rights to the
Latest news
-
GSK and Vir Biotech expand phase 3 COVID-19 antibody study
Vir Biotech has also signed a deal with Biogen for the process development and manufacturing of its antibodies for COVID-19. ... The Biogen agreement builds on Vir Biotech’s additional manufacturing agreements with China-based WuXi Biologics and Incheon
-
Moderna and GSK advance coronavirus vaccine candidates
Biotech company Moderna announced yesterday that its has released the first batch of its vaccine – mRNA-1273 – for human use. ... The company has partnered with China-based biotech company Clover Biopharmaceuticals on its protein-based coronavirus
-
Chi-Med cues up two more regulatory filings in cancer
in the China National Reimbursement Drug List (NRDL) at the next update later this year. ... NET) it is on course to file for approval in China before year-end.
-
Swedish biotech Calliditas signs China licensing deal for autoimmune candidate
The Swedish biotech launched its initial public offering (IPO) on the Stockholm Nasdaq last year, and has now secured a valuable partner which could unlock access to China's huge market. ... China is the world's largest market in terms of the number of
-
Gracell Bio developing faster, cheaper CAR-T production
Manufacturing can be cut from two weeks to one day. Gracell Bio has launched its new CAR-T production platform, and the China-based biotech claims its technology can reduce the
GSK and Vir Biotech expand phase 3 COVID-19 antibody study
Moderna and GSK advance coronavirus vaccine candidates
Chi-Med cues up two more regulatory filings in cancer
Swedish biotech Calliditas signs China licensing deal for autoimmune candidate
Gracell Bio developing faster, cheaper CAR-T production
More from news
Approximately 5 fully matching, plus 19 partially matching documents found.
Latest Intelligence
-
China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances
The nation’s biotech boom is rocking the laboratories and trading floors of the world as China secures a place at the forefront of innovative medicine, casting off its reputation as ... At the spear point is China’s emergence as the epicentre of
-
Deal Watch October 2016
150. AstraZeneca (UK). 3SBio. Distribution. Byetta, Bydureon (exanatide) for Type 2 diabetes in China. ... 100. Active Biotech (SE). NeoTx (IS). Licence. Tumour Targeting Superantigen ANYARA in phase I for oncology.
-
Russian innovation at the crossroads
The company is expected to launch its products in the US and China. ... Russia's biotech sector has high untapped potential. Rising risks but solid foundations.
China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances
Deal Watch October 2016
Russian innovation at the crossroads
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
Silence Therapeutics adds to leadership team
Prior to this, he held the same title at RiboBio, an oligonucleotide-focused biotech based in China, between 2011 and 2015, and served as vice president of technology development at RXi
Silence Therapeutics adds to leadership team
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Senior Account Manager
-
Competitive salary offered
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
-
Omnichannel Strategy Consultant
-
Competitive Salary
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- US demand for COVID-19 antibody treatments rising fast
- Data shows patients treated with Biogen's MS therapies mount an effective antibody response to COVID-19 vaccination
- EU “still interested” in Valneva COVID vaccine despite UK snub
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Sandoz completes acquisition of GSK’s cephalosporin business
- Biosimilars boosted by FDA's landmark ruling for Boehringer’s Cyltezo
- Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes
- Best practice in UK diabetes care recognised at prestigious national awards
- Live Webinar: Accelerating Revenue Cycle Performance in the Healthcare Industry
- The FDA vaccine advisory board recommends booster shots of both the J&J and Moderna vaccines
- Biogen's ALS drug tofersen misses phase 3 endpoint
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- US demand for COVID-19 antibody treatments rising fast
- Results of AstraZeneca’s TACKLE phase 3 trial show antibody combination reduces risk of severe COVID-19 or death
- David Hunt launches independent agency The Considered
- Live Webinar: Accelerating Revenue Cycle Performance in the Healthcare Industry
PMHub
Iguazu
Iguazu Ltd is a digital healthcare agency, delivering tactical and innovative solutions. WHAT WE DO We are Closed Loop Marketing...
Latest intelligence
- Breaking the silence: It’s time to talk about the menopause
- Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
- Committing time to making meaningful connections - top 5 tips
- Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
- News:
- Senior Analytics Specialist joins Research Partnership...
